REGOSTA – A multicentre exploratory phase II study describing the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone sarcomas

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514637-37-00

Acronym

ET18-272

Enrollment

Registered

2024-08-13

Start date

2020-02-11

Completion date

Unknown

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with bone sarcomas other than chordoma, who have no residual disease after their standard treatment sequence.

Brief summary

The primary endpoint will be the 36-month Relapse-Free Survival rate (36M-RFS). An event will be described as the recurrence of the disease, either local or distant, determined locally by the investigational staff.

Interventions

DRUGThe placebo refers to the IMP Stivarga 40 mg film-coated tablets

DRUGBAY 73-4506

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be the 36-month Relapse-Free Survival rate (36M-RFS). An event will be described as the recurrence of the disease, either local or distant, determined locally by the investigational staff.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026